Diffuse Large B-Cell Lymphoma | Topics

 
Oncology Peer Review On-The-Go: Emerging and Existing Treatment Regimens for Transplant-Ineligible DLBCL
June 30, 2021

For the “Oncology Peer Review On-The-Go” podcast, CancerNetwork® sat down with Gilles Salles, MD, to discuss different treatment regimens for transplant-ineligible DLBCL in this special edition episode.

Data Collected in Patients With DLBCL Reveal Real-World Trends for Use of Axi-Cel and Tisa-Cel
June 16, 2021

Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.

Relapsed/Refractory DLBCL Has Extended Response Duration With Naratuximab Emtansine Plus Rituximab
June 14, 2021

Clinical activity with the combination of naratuximab emtansine plus rituximab was observed in patients with relapsed or refractory diffuse large B-cell lymphoma.